Naturally Splendid Purchases Packaging Line and Announces Shares for Debt Transaction

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company") (FRANKFURT:50N) (TSX-V:NSP) (OTC PINK:NSPDF) is pleased to announce the purchase of a state of the art, automated packaging system capable of packaging a wide variety of food products in multiple formats

The packaging line has been ordered and will be installed in the Company's 20,000 square foot, Safe Quality Food (SQF) certified food manufacturing facility in Pitt Meadows, BC. The system is expected to be fully operational within 6-8 weeks.

This packaging system was selected for the array of products and packaging types it is designed to process and will be an integral component to packaging NATERA Plant Based Foods. The line will also be utilized for packaging existing products manufactured at the facility including our lines of plant-based bars and bites.

The Company recently announced signing a Letter of Intent (LOI) to be the exclusive Canadian manufacturer of plant-based, meat-replacement products for Flexitarian Foods, a division of Australia's largest plant-based food manufacturer. This enhanced packaging capability provides the ability to take an already extensive line of products, and through additional packaging options, increase the range of finished goods for retail and foodservice distribution opportunities.

Company CEO, Mr. J. Craig Goodwin reports, "Adding this packaging line immediately increases the range of products and services we can offer retail and foodservice clients. The strategy to leverage the resources of our existing facility and experienced production team by adding additional equipment specific to the production of NATERA Plant Based Foods, is being executed. The manufacturing lines to produce the plant-based product lines have been specified, and we will begin the systematic process of ordering, installing, and commissioning these lines once the definitive agreement with Flexitarian Foods is completed. This facility will be capable of manufacturing a wide range of plant-based alternatives for beef, chicken, pork, fish and shellfish once completed. We look forward to providing timely updates as these initiatives develop".

Shares For Debt Transaction

The Company announced today that its board of directors has approved the settlement of $255,225.11 in debt through the issuance of common shares of the Company (the "Debt Settlement"). Pursuant to the Debt Settlement, the Company will issue a total of 3,646,071 common shares of the Company at a price of $0.07 per share to certain creditors of the Company, including certain directors and officers of the Company (collectively, the "Creditors"). All 3,646,071 common shares will be subject to a hold period expiring four months and one day from the date of issuance.

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a Safe Quality Food Level 2 certified food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment.

The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19.

NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail or call Investor Relations at 604-465-0548 (ext.105)

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
CEO, President, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; customers will complete on sales contracts; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.


SOURCE:Naturally Splendid Enterprises Ltd.

View source version on

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sirona Biochem (TSXV:SBM)

Sirona Biochem Inc.

Keep reading...Show less
BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share

BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that the Company has completed the previously-announced strategic investment by Prevail Partners, LLC (" Prevail Partners ") in the Company (the " Investment "), in accordance with a stock purchase agreement (the " Agreement ") entered into between the Company and Prevail Partners on May 12, 2023. Pursuant to the Agreement, the Company issued 463,408 common shares (the " Shares ") to Prevail Partners (the " Issuance ") at a price per Share of US$8.63 for aggregate gross proceeds of US$4 million.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, announced today it is working with Pixie Brands @meetpixiebrands and Multi Brand Sampling Co @multibrandsmaplingco to promote and enhance sales at store level for all Boosh and Beanfields brands in BC.

Founded by CPG founder April Angelini, Pixie Brands offers a relationship-based, boots on the ground approach to help small and medium brands SHINE. They offer sales and distributor support and organize In-Store Events.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less


Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc:

"Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring significant benefits to patients suffering from very serious rare diseases in the U.S. and around the world.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

  • Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP.
  • Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for BriaCell's upcoming pivotal study, expected to commence in 2023.

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the Company has signed a Master Service and Technology Agreement ("MSTA") agreement with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO), to provide clinical services and technologies for BriaCell's upcoming pivotal study in advanced metastatic breast cancer. Services include clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and the use of InfoWork's integrated real-time data analytics platform, The Single Interface ® for clinical support and real-time data analysis.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
  Sirona Biochem Chief Scientific Officer Géraldine Deliencourt-Godefroy

Sirona Biochem Eyes Licensing Deal for Anti-aging Compound After Clinical Trial Results

Sirona Biochem (TSXV:SBM) is looking forward to securing a licensing deal after a clinical trial for its novel anti-aging compound TFC-1326 showed exceptional results, according to Géraldine Deliencourt-Godefroy, the company’s chief scientific officer.

“We have ongoing discussions with different partners that have shown interest in this compound … we have an event in Boston where we (will) share with other prospects (the) best results in order to find a way to license this compound,” Deliencourt-Godefroy said.

The clinical trial was conducted among 20 volunteers who used the compound in cream form two times a day for three months.

Keep reading...Show less

Latest Press Releases

Related News